Why Is Legend Biotech (LEGN) Stock Down -11.16% Today?
Key Takeaways
- Legend Biotech shares plunged approximately 11.2% in Monday trading, falling to around $19.74 from Friday's close of $22.22.
- The primary catalyst was the abrupt CEO transition announced Monday morning: Ying Huang, Ph.D., stepped down as Chief Executive Officer and board member, effective July 24, with Alan Bash named Interim CEO.
- A UBS downgrade on Friday from Buy to Neutral, with a price target cut from $49 to $28, compounded negative sentiment heading into the new trading week.
- Competitive concerns around Carvykti intensified after Johnson & Johnson's earnings call highlighted the Tecvayli-Darzalex combination as having "potential for cure" in second-line multiple myeloma.
- Broader biotech weakness and lingering geopolitical concerns related to Legend's historical ties to China-based Genscript added additional headwinds.
- Traders are now watching for details on the permanent CEO search and upcoming Q2 earnings, expected in August.
Opening Summary
LEGN, the global cell therapy leader behind the CAR-T treatment Carvykti, saw its shares tumble roughly 11.2% on Monday, sliding to approximately $19.74 after closing at $22.22 on Friday, July 24. The sharp decline came as investors reacted to the company's announcement that CEO Ying Huang had stepped down after seven years at the helm, with CARVYKTI Business Unit President Alan Bash taking over as Interim Chief Executive Officer. The leadership shake-up, layered on top of a UBS downgrade late last week and mounting competitive pressure in the multiple myeloma space, sent the stock to levels not seen in months.
CEO Transition Shakes Investor Confidence
The most immediate driver of Monday's selloff was Legend Biotech's pre-market announcement that Ying Huang, Ph.D., had resigned as CEO and from the Board of Directors, effective July 24, 2026. Dr. Huang — who guided LEGN from a pioneering cell therapy startup to a commercial-stage global biotechnology company — will remain as an advisor through August. The Board appointed Alan Bash, current President of the CARVYKTI Business Unit, as Interim CEO while launching a comprehensive search for a permanent successor.
CEO departures, particularly abrupt ones without a named permanent replacement, often rattle biotech investors who view leadership stability as critical to navigating complex clinical pipelines and commercial execution. While Chairman Frank Zhang expressed "full confidence" in Bash's ability to provide continuity, the market's reaction suggests unease about the timing and circumstances surrounding the transition, especially given the competitive pressures already weighing on the company.
UBS Downgrade Compounds the Pain
Monday's decline did not occur in a vacuum. On Friday, July 24, UBS downgraded LEGN from Buy to Neutral and slashed its price target from $49 to $28. The downgrade contributed to a 5.6% decline that same session. The analyst action reflected growing concerns about Carvykti's competitive positioning and market dynamics in the multiple myeloma treatment landscape.
The UBS move followed a broader pattern of mixed analyst sentiment in recent weeks. While firms like H.C. Wainwright maintained Buy ratings with a $65 target, others including TD Cowen and JPMorgan adopted more cautious stances. The divergence underscores the uncertainty surrounding Legend Biotech's growth trajectory as competitor therapies gain traction.
Competitive Threats to Carvykti Intensify
Underlying the recent stock weakness is a tangible competitive threat to Carvykti, Legend's flagship CAR-T therapy co-developed with Johnson & Johnson's (JNJ) Janssen unit. During J&J's July 15 earnings call, Worldwide Chair of Innovative Medicine Jennifer Taubert suggested that the off-the-shelf combination of Tecvayli and Darzalex holds "the potential for cure" in second-line multiple myeloma — phrasing previously associated with Carvykti.
That comment, combined with Tecvayli's 64% year-over-year U.S. sales jump to $186 million in Q2 following its second-line approval in March, raised fears that J&J may be prioritizing its wholly owned therapies over the partnered Carvykti. Although Carvykti still posted record sales of $657 million in Q2 (up 10% sequentially), the market reacted negatively to the perceived shift in J&J's commercial narrative. Adding to these concerns, Gilead Sciences' (GILD) rival CAR-T therapy anito-cel is expected to launch later this year, potentially further fragmenting the market.
Market Context and Trading Activity
Monday's selloff pushed LEGN further below key technical levels, with the stock now trading well beneath its 50-day simple moving average of approximately $29.68. The decline extends a painful month-long drawdown that has seen shares lose roughly a quarter of their value since late June. Broader biotech sentiment has also been mixed, with the sector grappling with interest rate uncertainty and rotation pressures.
The stock's downward momentum traces back to mid-July, when shares fell approximately 10% on July 15 following the J&J earnings call commentary, followed by additional selling tied to a $226 million public offering priced at $29.35 per ADS in mid-June. Since hitting levels near $30 in early July, LEGN has declined steadily, with Monday's CEO transition news accelerating the descent.
What Comes Next for LEGN
Investors will be closely monitoring Legend Biotech's upcoming second-quarter earnings report, expected in August, for updates on Carvykti sales momentum, pipeline progress including the LB2501 and LB2505 programs, and any color on the CEO search. The company's ability to articulate a clear leadership succession plan and reaffirm its commercial strategy will be critical to restoring confidence.
Key risks include the potential launch of Gilead's anito-cel, evolving competitive dynamics within J&J's own oncology portfolio, and ongoing geopolitical scrutiny related to Legend's historical ownership ties to China-based Genscript. On the clinical side, data readouts from the company's solid-tumor CAR-T program (LB2102, partnered with Novartis) and next-generation candidates could serve as catalysts — though timelines remain uncertain. For now, the immediate priority is stabilizing leadership and reassuring the market that Carvykti's growth story remains intact.
Trending AI Robots
In times of heightened stock volatility, traders and investors increasingly turn to AI-driven tools for data-backed decision-making. Tickeron offers hundreds of AI trading bots covering thousands of tickers, spanning diverse strategies, timeframes, and performance metrics. Among these, only the strongest performers under current market conditions are featured in a curated Trending AI Robots section. These bots vary by trading approach — from swing trading to trend following — and are continuously evaluated based on real-time results. For those seeking algorithmic insights to navigate turbulent markets, exploring the Trending AI Robots page may provide a useful starting point.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
LEGN in upward trend: price may jump up because it broke its lower Bollinger Band on July 27, 2026
LEGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 43 cases where LEGN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LEGN's RSI Indicator exited the oversold zone, of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 10, 2026. You may want to consider a long position or call options on LEGN as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for LEGN just turned positive on August 07, 2026. Looking at past instances where LEGN's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where LEGN advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LEGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for LEGN entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.434) is normal, around the industry mean (20.230). P/E Ratio (0.000) is within average values for comparable stocks, (25.707). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.848). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (3.183) is also within normal values, averaging (466.836).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. LEGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LEGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications
Industry Biotechnology
Advertisement